Drugs & Therapy Perspectives

, Volume 13, Issue 8, pp 1–5 | Cite as

Infliximab Provides Short-Term Relief in Crohn’s Disease

New Drugs and Disease Management


Cocaine Infliximab Adis International Limited Cocaine Abuse Inflammatory Bowel Disease Questionnaire 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn’s disease and rheumatoid arthritis. BioDrugs 1998 Nov; 10 (5): 397–422PubMedCrossRefGoogle Scholar
  2. 2.
    Canada T. Focus on infliximab: a TNF-alpha inhibitor that reduces intestinal inflammation in Crohn’s disease refractory to conventional therapy. Formulary 1998 Dec; 33: 1171–89Google Scholar
  3. 3.
    Caspi A. Infliximab: a novel agent for the treatment of active, moderate-to-severe Crohn’s disease. P&T 1998 Oct; 509–14Google Scholar
  4. 4.
    Hanauer SB, Meyers S. Management of Crohn’s disease in adults. Am J Gastroenterol 1997 Apr; 92: 559–66PubMedGoogle Scholar
  5. 5.
    Glickman RM. Inflammatory bowel disease: ulcerative colotis and Crohn’s disease. In: Wilson JD, et al., editors. Harrison’s principles of internal medicine, 12th ed. New York: McGraw-Hill, 1991: 1268–81Google Scholar
  6. 6.
    Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 1997 Oct 9; 337: 1029–35PubMedCrossRefGoogle Scholar
  7. 7.
    Rutgeerts P, D’Haens G, van Deventer SJH, et al. Retreatment with anti-TNFα chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn’s disease [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: A 1078Google Scholar
  8. 8.
    Centocor Inc. Remicade (infliximab) for IV injection prescribing information for USA. 12 Aug 1998 (Data on file)Google Scholar
  9. 9.
    Present D, Mayer L, van Deventer SJH, et al. Anti-TNF-alpha chimeric antibody (cA2) is effective in the treatment of the fistulae of Crohn’s disease: a multicenter, randomized, double-blind, placebo-controlled study [abstract]. Am J Gastroenterol 1997 Sep; 92: 1746Google Scholar
  10. 10.
    McCabe RP, Woody J, van Deventer S, et al. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A962Google Scholar
  11. 11.
    ‘Dear Doctor’ letter for infliximab in the US. Reactions 1998 Dec 12; 731: 3Google Scholar
  12. 12.
    McClellan K. Cytokine-target therapies cost effective in Crohn’s disease? Pharmacoecon & Outcomes News 1999 Jan 23; 196: 3–4Google Scholar
  13. 13.
    Centocor’s infliximab launched in US. Scrip 1998 Oct 14; 2378: 20Google Scholar

Copyright information

© Adis International LTD 1999

Personalised recommendations